What a lovely bit of news to read this morning!
$20m annual revenue so only currently valued at 4 x revenue. Also in terms of earnings we can assume a current run rate of $3m per quarter or $12m annualised. That's a P/E ratio of only 7.2
Given rapid (and consistent) growth of company, this is still very under valued IMO.
Not many stocks I've ever owned where I have a 400% profit and still think it's undervalued![]()
- Forums
- ASX - By Stock
- BIG
- Ann: FY17 Cash Revenue Guidance Update
Ann: FY17 Cash Revenue Guidance Update, page-10
-
- There are more pages in this discussion • 76 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Featured News
Add BIG (ASX) to my watchlist
Currently unlisted public company.
The Watchlist
RCE
RECCE PHARMACEUTICALS LTD
James Graham / Dr Alan Dunton, MD & CEO / Non-Executive Director
James Graham / Dr Alan Dunton
MD & CEO / Non-Executive Director
SPONSORED BY The Market Online